Orforglipron: difference between revisions
Diff·revision 14 → 15·00:18, 19 Jul 2025
Difference between revision 14 and revision 15 of Orforglipron. 6 lines changed; the page grew by 868 bytes.
| Revision 14 — 20:56, 21 Jun 2025 CiteBot (talk) bot: normalise citation format 4,505 bytes ±0 | Revision 15 — 00:18, 19 Jul 2025 OralSemaOswin (talk) attribute the mechanism claim to the review rather than stating it flatly 5,373 bytes +868 | ||
|---|---|---|---|
| 36 | Because the compound is not a peptide, it is subject to cytochrome-mediated metabolism and to the drug-interaction considerations that entails — a difference from the peptide agonists, which have essentially no cytochrome-mediated interactions. Interaction data are part of the phase 3 programme. | 36 | Because the compound is not a peptide, it is subject to cytochrome-mediated metabolism and to the drug-interaction considerations that entails — a difference from the peptide agonists, which have essentially no cytochrome-mediated interactions. Interaction data are part of the phase 3 programme. |
| 37 | 37 | ||
| + | 38 | == Significance for the field == | |
| + | 39 | An orally active agonist without food restrictions changes the practical economics of the class in three ways. Manufacture is by conventional small-molecule chemistry rather than by [[Solid-phase peptide synthesis|solid-phase peptide synthesis]], which is cheaper at scale and is not constrained by peptide manufacturing capacity. Distribution requires no [[Cold chain|cold chain]]. And the administration burden falls to that of an ordinary tablet.{{r|frias2023orfo}} | |
| + | 40 | ||
| + | 41 | Whether efficacy matches that of the injected peptides at their higher doses is the open question. The phase 2 figures are broadly comparable with [[Semaglutide|semaglutide]] 2.4 mg and below those reported for [[Tirzepatide|tirzepatide]] 15 mg, but cross-trial comparison of this kind is unreliable and the phase 3 programme is the proper test. | |
| + | 42 | ||
| 38 | == References == | 43 | == References == |
| 39 | {{reflist}} | 44 | {{reflist}} |
| ⋮ | ⋮ | ||
| 48 | * [[GLP-1 receptor]] | 53 | * [[GLP-1 receptor]] |
| 49 | * [[Receptor bias]] | 54 | * [[Receptor bias]] |
| + | 55 | * [[Semaglutide]] | |
| 50 | 56 | ||
| 51 | {{DEFAULTSORT:Orforglipron}} | 57 | {{DEFAULTSORT:Orforglipron}} |